Stryker Corporation
- Open
- 317.16
- Day high
- 318.55
- Day low
- 314.00
- Prev close
- 314.80
- Volume
- 154K
- Mkt cap
- $121.1B
- P/E (TTM)
- 36.2
- EPS (TTM)
- $8.73
- P/B
- 5.3
- P/S
- 4.8
- Yield
- 0.56%
- Per share
- $1.76
- ▼Insiders net selling -$100.7M over the last 3 months (0 open-market buys, 14 sales)
- 🏛Institutions mixed (13F)
Stryker Corporation (SYK) is a Healthcare company listed on NYSE. The stock is down 21% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 14 sales (SEC Form 4).
Stryker Corporation (SYK) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 11 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
SYK earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 30, 2026 | $2.98 | $2.60 | -12.8% | $6.0B | -5.0% |
| Jan 29, 2026 | $4.40 | $4.47 | +1.6% | $7.2B | +0.7% |
| Oct 30, 2025 | $3.13 | $3.19 | +1.9% | $6.1B | +0.2% |
| Jul 31, 2025 | $3.07 | $3.13 | +2.0% | $6.0B | +1.4% |
| May 1, 2025 | $2.71 | $2.84 | +4.8% | $5.9B | +3.1% |
| Jan 28, 2025 | $3.87 | $4.01 | +3.6% | $6.4B | +1.2% |
| Apr 30, 2024 | $2.35 | $2.50 | +6.4% | $5.2B | +2.7% |
| Jan 30, 2024 | $3.27 | $3.46 | +5.8% | $5.8B | +3.9% |
| Nov 2, 2023 | $2.44 | $2.46 | +0.8% | $4.9B | +1.0% |
| Aug 3, 2023 | $2.38 | $2.54 | +6.7% | $5.0B | +3.5% |
| May 1, 2023 | $2.00 | $2.14 | +7.0% | $4.8B | +4.8% |
| Jan 31, 2023 | $2.84 | $3.00 | +5.6% | $5.2B | +4.8% |
SYK insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 29, 2026 | Fletcher Robert Sofficer: VP, Chief Legal Officer | Sell | 165 | $305.66 |
| May 29, 2026 | Fletcher Robert Sofficer: VP, Chief Legal Officer | Sell | 258 | $308.79 |
| May 29, 2026 | Fletcher Robert Sofficer: VP, Chief Legal Officer | Sell | 120 | $304.23 |
| May 29, 2026 | Fletcher Robert Sofficer: VP, Chief Legal Officer | Sell | 125 | $310.22 |
| May 29, 2026 | Fletcher Robert Sofficer: VP, Chief Legal Officer | Sell | 1,067 | $307.30 |
| May 29, 2026 | Fletcher Robert Sofficer: VP, Chief Legal Officer | Sell | 2,809 | $306.56 |
| May 28, 2026 | STRYKER RONDA Edirector | Sell | 114,059 | $312.44 |
| May 28, 2026 | STRYKER RONDA Edirector | Sell | 44,060 | $313.35 |
| May 28, 2026 | STRYKER RONDA Edirector | Sell | 21,807 | $310.77 |
| May 28, 2026 | STRYKER RONDA Edirector | Sell | 115,960 | $311.60 |
| May 28, 2026 | STRYKER RONDA Edirector | Sell | 3,707 | $315.11 |
| May 28, 2026 | STRYKER RONDA Edirector | Sell | 10,407 | $314.38 |
| May 12, 2026 | Fink M Kathrynofficer: VP, Chief HR Officer | Sell | 3,500 | $283.45 |
| May 12, 2026 | Fink M Kathrynofficer: VP, Chief HR Officer | Sell | 5,220 | $283.85 |
| May 12, 2026 | Fink M Kathrynofficer: VP, Chief HR Officer | Option | 9,732 | $154.14 |
Source: SYK SEC Form 4 filings, latest May 29, 2026. For informational purposes only — not investment advice.
See the full SYK insider & 13F page →Stryker Corporation company profile
Overview
Stryker Corporation (NYSE:SYK) is a leading American medical technology company founded in 1941 and headquartered in Kalamazoo, Michigan. The company has grown from a small medical device manufacturer into one of the world's largest medical technology corporations, with operations spanning approximately 75 countries. Stryker went public in 1980 and has established itself as a dominant player in the medical device industry through decades of innovation, strategic acquisitions, and global expansion.
Business
Stryker operates in the medical device industry, which encompasses the design, manufacture, and distribution of equipment and implants used in medical procedures. The medical device sector serves as a critical component of modern healthcare infrastructure, providing tools that enable surgeons to perform complex procedures and improve patient outcomes. The company operates through two primary business segments: 1. **MedSurg and Neurotechnology** (approximately 60% of revenue): This segment encompasses surgical equipment and navigation systems that guide surgeons during operations, endoscopic systems for minimally invasive procedures, patient handling equipment used in hospitals, emergency medical equipment including defibrillators, and intensive care disposable products. The neurotechnology portion includes specialized devices for brain and skull surgeries, products for treating strokes through minimally invasive techniques, and craniomaxillofacial implants for facial reconstruction. This segment also offers reprocessed medical devices, which involves refurbishing single-use medical equipment to extend its lifecycle. 2. **Orthopaedics and Spine** (approximately 40% of revenue): This segment focuses on implants used in joint replacement surgeries, particularly hip and knee replacements, which are among the most common orthopedic procedures. It also includes trauma and extremities products for treating fractures and injuries, as well as spinal implant systems used to treat spinal injuries, deformities, and degenerative conditions. A key differentiator in this segment is the Mako robotic-assisted surgery platform, which uses robotic technology to help surgeons perform more precise joint replacement procedures.
Revenue model
Stryker generates revenue primarily through direct product sales to healthcare providers, including hospitals, ambulatory surgical centers, and individual physicians. The company sells its products through a combination of company-owned subsidiaries, direct sales forces, and third-party distributors across its global markets. The business model benefits from several recurring revenue streams. Beyond initial equipment sales, Stryker generates ongoing revenue from disposable products, service contracts, and replacement parts. For example, when a hospital purchases a Mako robotic system, it creates a long-term relationship where the hospital continues to purchase specialized instruments and disposables for each procedure performed on the system. Several factors influence Stryker's profitability margins. **Positive margin drivers** include the company's premium pricing power due to its innovative products and strong brand reputation, the recurring nature of disposable products and service revenues, and operational leverage from its scale in manufacturing and distribution. The company's robotic platforms particularly command premium pricing and create customer stickiness. **Margin pressures** come from rising raw material costs, supply chain disruptions, competitive pricing pressure in commodity-like products, regulatory compliance costs, and the significant research and development investments required to maintain technological leadership. Additionally, hospital budget constraints and healthcare cost containment efforts can pressure pricing, while tariffs and currency fluctuations affect international operations. Recent earnings calls indicate the company is actively managing a $200 million tariff impact through pricing initiatives, manufacturing optimization, and operational efficiencies, demonstrating its ability to adapt to external cost pressures while maintaining growth momentum.
Competitive moat
Stryker possesses a strong competitive moat built on several interconnected advantages. The company's **technological leadership**, particularly in robotic-assisted surgery through its Mako platform, creates significant switching costs for healthcare providers. Once a hospital invests in a Mako system, it becomes deeply integrated into their surgical workflows, and surgeons develop expertise specific to the platform, making it costly and disruptive to switch to competitors. The company's **extensive product ecosystem** reinforces this moat - when hospitals adopt one Stryker product, it often leads to adoption of complementary products within the same system. For instance, the Mako robotic platform drives demand for Stryker's implants, instruments, and disposables. The company's **regulatory expertise** and established relationships with regulatory bodies worldwide create barriers for new entrants, as medical device approval processes are lengthy, expensive, and require deep regulatory knowledge. **Scale advantages** in manufacturing, research and development, and global distribution provide cost efficiencies that smaller competitors cannot match. Stryker's ability to invest billions in R&D annually and maintain a global sales force gives it significant competitive advantages. However, the moat faces potential challenges. Large diversified competitors like Johnson & Johnson and Medtronic have comparable resources and technological capabilities. The medical device industry is subject to rapid technological change, and breakthrough innovations from startups or tech companies could potentially disrupt established players. Additionally, increasing healthcare cost pressures and the rise of value-based care models could commoditize some product categories, though Stryker's focus on premium, outcome-improving technologies helps mitigate this risk.
Risks & safety
Stryker demonstrates a strong financial position with adequate margin of safety for investors: **Liquidity and Solvency:** - Cash and short-term investments of $2.3 billion as of Q1 2025 - Strong free cash flow generation of $3.5 billion in 2024 - Current ratio of 1.64, indicating solid short-term liquidity - Manageable debt-to-equity ratio of 0.31 (Q1 2025) **Valuation Metrics:** - Trading at 54.3x P/E ratio (Q1 2025), reflecting premium valuation - EV/EBITDA of 46.0x (Q1 2025), elevated due to recent acquisitions - Price-to-book ratio of 3.1x, reasonable for a technology-focused healthcare company **Other Considerations:** - Consistent double-digit revenue growth and margin expansion trajectory - Strong return on equity of 14.5% (2024), indicating efficient capital allocation - Diversified revenue streams across multiple medical specialties reduce concentration risk - However, premium valuation leaves limited margin for execution disappointments
Recent development
Over the past few years, Stryker has executed several strategic initiatives to accelerate growth and expand its market presence. The company has been particularly active in **mergers and acquisitions**, completing seven acquisitions in 2024 alone, including the significant $4.9 billion acquisition of Inari Medical to enter the peripheral vascular market. The company also divested its U.S. Spinal Implants business to focus resources on higher-growth segments. **Product innovation** has been a key focus, with the successful expansion of the Mako robotic platform beyond knee and hip procedures to include spine and shoulder applications. The company has launched several new products including the LIFEPAK 35 defibrillator, the Pangea trauma plating system, and various advanced surgical navigation systems. These innovations have contributed to strong double-digit growth rates across most business segments. **International expansion** has been another strategic priority, with international markets consistently outpacing U.S. growth rates. The company has been particularly successful in markets like Japan, Australia, and Europe, leveraging products like the Mako robotic system and advanced camera platforms to gain market share. The company has also focused on **operational excellence**, implementing pricing initiatives and manufacturing optimizations to achieve its target of 200 basis points of margin expansion by 2025. Recent management changes, including the appointment of Preston Wells as CFO, reflect the company's preparation for its next phase of growth.
SYK company profile · for informational purposes only — not investment advice.
Track SYK with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free